Navigation Links
Pfizer Suspends Chronic Pain Studies in Tanezumab Clinical Trial Program; Some Studies Continue in Areas of Unmet Medical Need
Date:7/19/2010

NEW YORK, July 19 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced, at the request of the U.S. Food and Drug Administration (FDA), the suspension of the chronic low back pain and painful diabetic peripheral neuropathy studies in the clinical program for the investigational compound tanezumab. Investigation of the compound continues in some areas of high unmet medical need, including cancer pain.

(Logo:  http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO )

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO )

The FDA's request follows further consideration of reports of adverse events in osteoarthritis patients taking tanezumab, and the agency's concerns regarding the potential for such events in other patient populations in which the compound is being studied.  Pfizer announced the suspension of tanezumab studies in patients with osteoarthritis in a June 23 press release.  

For studies on clinical hold, recruitment of new patients and the dosing of existing patients are suspended.  

Pfizer will continue to work with the FDA to reach a common understanding about the appropriate scope of continued clinical investigation of tanezumab.

Pfizer Inc.: Working together for a healthier world™

At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life.  We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines for people and animals.  Our diversified global health care portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and many of the world's best-known consumer products.  Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time.  Consistent with our responsibility as the world's leading biopharmaceutical company, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world.  For more than 150 years, Pfizer has worked to make a difference for all who rely on us.  To learn more about our commitments, please visit us at www.pfizer.com.


'/>"/>
SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Pfizer and SMC Collaborate on Liver Cancer
2. Pfizer to Present More Than 40 Abstracts on Pre-Clinical, Clinical and Outcomes Research at Alzheimers Association International Conference on Alzheimers Disease
3. Pfizer Inc and GoIndustry DoveBid Partner to Auction Surplus Equipment from R&D Facilities Across the United States
4. Pfizer Invites Public to View and Listen to Webcast of August 3 Conference Call With Analysts
5. Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg®
6. Pfizer And Epocrates Partner To Give Healthcare Providers Access To Medical Information Specialists For Medication Questions
7. Pfizer Appoints Mikael Dolsten President of Worldwide Research and Development
8. Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
9. Pfizer Reigns Supreme After Patent Cliff as Humira Kicks Avastin off Top Spot
10. Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
11. Pfizers Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... Feb. 5, 2016  ivWatch, a medical devices company, is ... Award granted by Governor Terry McAuliffe,s office. ivWatch ... February 25th at an event to be held at the ... award honors professionals and business that have made significant contributions ... Logo - http://photos.prnewswire.com/prnh/20160205/330117LOGO ...
(Date:2/5/2016)... Feb. 5, 2016  Patients in Alabama ... ultrasound (HIFU) therapy no longer have to travel out of ... partnership with Urology Centers of Alabama to provide ... procedure for qualifying patients. Alabama ... the treatment of prostate cancer using many different modalities. They ...
(Date:2/5/2016)... Feb. 5, 2016 ... of the "Global Musculoskeletal Partnering 2010-2016: ... profile to their offering. --> ... of the "Global Musculoskeletal Partnering 2010-2016: ... profile to their offering. --> ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... 05, 2016 , ... Steven Tonkinson, 36, of Coconut Grove, Florida, ran the ... started in 2003. This year, he ran all 26.2 miles with a green 25-pound ... the Miami Heat. , This Sunday, while many are watching the Superbowl, Steven Tonkinson ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held on April ... in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the ... lives with Parkinson’s disease and is the architect of this informative event to raise ...
(Date:2/5/2016)... ... 05, 2016 , ... After years as an active staff surgeon and having ... surgeon Dr. Wayne Carman transitioned to chief of the Division of Plastic Surgery at ... term as chief and began a second three-year term in January of 2016. , ...
(Date:2/5/2016)... ... February 05, 2016 , ... Regular gym users know ... having to wait longer to access the treadmills. It’s a predictable trend. After the ... lose weight and get in shape by joining gyms, starting new walking or running ...
(Date:2/5/2016)... ... ... Dr. Justin Scott and Dr. Lydia Muccioli of Pure Dental Health ... in need. The event is scheduled to take place on February 27, 2016 from ... dental care to community members in need. Each patient will be given the opportunity ...
Breaking Medicine News(10 mins):